AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05842759 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention threshold
Description: Lower mean arterial pressure intervention threshold will be 75 mmHg: continuous norepinephrine infusion will be started when mean arterial blood decreases below 75 mmHg
Study NCT04637815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Network Intervention
Description: Every 2 weeks, residents attend meetings with their case manager. These meetings are customized to the needs of the resident at the time of the meeting. Participants randomized into the Motivational Network Intervention arm are offered an additional discussion about their social networks. Case managers ask participants to answer a series of standardized questions about people they know. After these questions are answered, case managers show participants a series of images representing these answers. While showing these images, case mangers engage the participant in discussions about what they notice using Motivational Interviewing techniques. The goal is to discuss what the participant wants to change and state strategies about achieving these changes.
Study NCT04637815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Residents attend regular case management meetings with their case managers as a condition of their residency in the housing program. These sessions are customized do the needs of the resident at the time of the meeting. Participants randomized into the usual care arm will be offered these sessions every 2 weeks.
Study NCT04928599 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04928599 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Complete interview
Study NCT05921435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D958
Description: A single dose of 1tablet under fasting condition
Study NCT04928599 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study NCT04683029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab Dose 1 will be administered intravenously.
Study NCT04683029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab Dose 2 will be administered subcutaneously.
Study NCT04683029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously or subcutaneously.
Study NCT04467086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Propranolol enterally at a starting dose of 20mg every 6h for 2-4 doses, and then re-assessed for upwards titration every 24 hours (+/- 6 hours) at 10mg dose increases depending on clinical response. Maximum dose of 60mg every 6h. Titration decision to be made by clinical team at daily rounds.~Daily titration will be guided by hemodynamic markers indicative of the expected sympatholysis from propranolol. Upward titration of propranolol should coincide with a downward titration in sedatives until a minimum level of sedative infusion is reached (propofol \<0.5mg/kg/h or midazolam \<1.0mg/h). Nurses will be instructed at each assessment to determine if sedative targets can be achieved with lower doses of sedatives. Daily upward titration of propranolol will be recommended if none of these conditions are met: (1)HR\<70 beats/min, (2) Mean Arterial Pressure \<70 mmHg or (3) norepinephrine or equivalent vasopressor dose increase to >0.15 mcg/kg/min.
Study NCT05096065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 120 mg - QD- Treatment A
Description: If the subject during Treatment A meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the First Treatment Cycle), in the Second Treatment Cycle, she will be assigned Treatment B - 80 mg (2 x 40 mg tablets) (QD), with food-intake restrictions.~If the subject during Treatment A fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the First Treatment Cycle), then she will be switched to the Second Treatment Cycle with Treatment D - 60 mg (BID) with food intake restrictions.
Study NCT05096065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 80 mg - QD - Treatment B
Description: If the subject on Treatment B meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment C - 60 mg (QD) with food-intake restrictions.~If the subject on Treatment B does not meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Study NCT05096065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 60 mg - QD - Treatment C
Description: For up to 29 consecutive days with food-intake restrictions
Study NCT05096065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 60 mg - BID - Treatment D
Description: If the subject on Treatment D fails to meet the pharmacodynamic success criterion (i.e., if estradiol level ≥20 pg/mL on Treatment Day 29 of the Second Treatment Cycle), she will be discontinued from the study following completion of the Second Treatment Cycle.~If the subject during Treatment D meets the pharmacodynamic success criterion (estradiol level \<20 pg/mL on Treatment Day 29 of her Second Treatment Cycle), then she will be switched to the Third Treatment Cycle with Treatment E - 40 mg (BID) with food intake restrictions.
Study NCT05096065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Description: For up to 29 consecutive days with food-intake restrictions
Study NCT05626101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: Intravsical induction and maintenance BCG injections.
Study NCT05626101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravsical induction and maintenance gemcitabin injections.
Study NCT05590585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Administered by subcutaneous (SC) injection once every 2 weeks (Q2W) following a loading dose
Study NCT05590585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical emollient (moisturizer)
Description: Moisturizer should be applied twice daily, as per physician's recommendation, as defined in protocol.
Study NCT05548517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Description: 9-hour eating window
Study NCT05548517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: daily calorie restriction
Study NCT05548517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie Restriction
Description: daily calorie restriction
Study NCT05657028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: -In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
Study NCT05657028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
Study NCT05705349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: Fixed dose combination tablet containing DOR/ISL 100 mg/0.25 mg taken by mouth.
Study NCT05705349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: Fixed dose combination tablet containing BIC/FTC/TAF 50 mg/200 mg/25 mg taken by mouth.
Study NCT05705349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DOR/ISL
Description: Placebo tablet matched to DOR/ISL tablet taken by mouth.
Study NCT04765007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based stress reduction
Description: Eight sessions of two hours and a half, one day per week during eight weeks. In addition, patients will perform a day of intensive silent practice of 6-8 hours of duration.~The content of each session balances three activities: the presentation of a topic, moments of dialogue and group exploration (using appreciative inquiry) and a Mindfulness practice.~The sessions will take place in online format, through the google meet application
Study NCT04765007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimal intervention
Description: A guided meditation program of eight weeks of duration will be provided to the patients and they will be informed about the procedure and the beneficial effects of the therapy.
Study NCT05705349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF tablet taken by mouth.
Study NCT06103162 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: flexible feeding plate
Description: One mm thick clear thermoplastic sheet was adapted over the cast using a vacuum-forming machine.
Study NCT05592015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT04838314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional analgesia
Description: Peri operative regional analgesia by bilateral ESP catheter for 72h
Study NCT05515848 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this retrospective study.
Study NCT05360836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatment via telerehabilitation
Description: Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, massage application for 5 minutes, passive, active assistive normal range of motion. Ice application. After 4 weeks strenghtening exercise. The treatment time 8 weeks.
Study NCT05360836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative treatmen + motor imagery
Description: Patients will do their exercises in the form of a WhatsApp video call or a Zoom video call.~Contrast bath, 5-minute massage, passive, active auxiliary normal range of motion. Ice application. Strengthening exercise after 4 weeks. The duration of treatment is 8 weeks. This group applies motor images for a maximum of 5 minutes. They will implement functionality-based motor images.
Study NCT05440292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: For each stimulation day, low-frequency (1 Hz) ,1800 pulses(intensity of 100% resting motor threshold(RMT), duration 30 min) rTMS stimulation were delivered on the hotspot of unaffected hemisphere(Hotspot-rTMS Group) and the motor task activation poin of unaffected hemisphere(fMRI-rTMS Group). rTMS which guided by individualized navigation delivery 5 days a week for 4 weeks.
Study NCT05551806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help cognitive behavioural therapy
Description: The online CBT-I course will consist of an introductory module, followed by 6 weekly modules, incorporating the key CBT-I components, including sleep hygiene education, stimulus control, sleep restriction, relaxation training, and cognitive therapy.
Study NCT05950568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block typen II
Description: A 22 gauge needle was positioned between the quadratus lumborum muscle posterior border and the erector spinae muscle in the thoracolumbar fascia's middle layer
Study NCT05950568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block III
Description: A 22 gauge needle was positioned between the psoas and quadratus lumborum muscles at the anterior fascia lumbosacral
Study NCT05950568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: A 22 gauge needle was positioned between the internal oblique and transversus abdominis muscles
Study NCT05577975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Aspara @ smart grower
Description: The program will consist of three face-to-face (F-T-F) horticultural activity training session for a group of 6-8 participants and then biweekly telephone follow-up for 8-week home-based horticultural intervention. The home-based program contains different horticultural, cognitive and multisensory stimulation activities such asking the PWD and the family caregiver to record the sense of touch and odor when taking care of the plant and the various changes of the plants by using the smart grower. Program evaluation will be conducted through focus groups with 15 participants with different levels of stress reduction after the intervention.
Study NCT06423235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular dose of JiRui® Prunella oral liquid
Description: Take 10ml twice a day
Study NCT06423235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2x regular dose of JiRui® Prunella oral liquid
Description: Take 20ml twice a day
Study NCT06423235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: regular dose of placebo
Description: Take 10ml twice a day
Study NCT06423235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2x regular dose of placebo
Description: Take 20ml twice a day
Study NCT05669443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional PEEP
Description: Maintain positive end expiratory pressure at 5 cmH2O throughout the surgery.
Study NCT05669443 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: optimized PEEP
Description: Immediately after induction of anesthesia, the patient remains unapplied to PEEP. After pneumoperitoneum + Trendelenburg posture, an appropriate PEEP value is derived using electrical impedance tomography (airtom®). And then derived value ( = optimized PEEP value) is applied until the end of the operation.
Study NCT05054530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMA106 Injection
Description: GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
Study NCT05054530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GMA106 Matching Placebo
Description: Matching Placebo for GMA106
Study NCT04630093 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Panel-based pharmacogenetic genotyping
Description: A DNA sample by saliva (via mouthwash swish and expectorate collection) or buccal cell (via buccal brush) will be obtained for pharmacogenetic testing and questionnaires will be administered at baseline and then again at 3 months and 6 months after receiving PGx results.
Study NCT04528810 — intervention group
Intervention type: OTHER
Intervention: not applicable (Observational Study)
Description: This is an observational study and does not include interventions.
Study NCT06642350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrostimulation
Description: 10 weeks of WB-EMS 1.5x 20 min/week
Study NCT06642350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Training Therapy
Description: 10 weeks of MTT 2x 45 min/week
Study NCT05086627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients were treated with Tislelizumab on the first day of each cycle of CapeOX (Capecitabine+Oxaliplatin).
Study NCT05086627 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short-course radiotherapy
Description: Patients were treated with short-course neoadjuvant radiotherapy
Study NCT05658809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: Patients will be divided into 2 groups group will be treated with total thyroidectomy and the other group will be treated with hemithyroidectomy
Study NCT05350709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mirror therapy
Description: 15 patients will be recruited to each group. Patients will receive a total of 20 sessions of treatment, 5 days a week.
Study NCT05147376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin mouthwash
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
Study NCT05147376 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo mouthwash
Description: Rinse with 10 ml for 1 minute, twice a day for 28 days after brushing in the morning and at night, following proper oral hygiene and avoid taking any liquid or food for 30 minutes after rinsing.
Study NCT05882812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.
Study NCT05882812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.
Study NCT05882812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.
Study NCT06095219 — intervention group
Intervention type: OTHER
Intervention: Non- contrast Magnetic Resonance Imaging (MRI) of the hip
Description: Asymptomatic volunteers will undergo a non-contrast MRI of the hip at 3 Tesla. Following this, MRI images will be automatically segmented utilizing a validated artificial intelligence based algorithm to calculate 3D outcome parameters.
Study NCT06095219 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) of the hip with intra-articular contrast agent
Description: The data was derived from a retrospective study involving patients at Inselspital's outpatient clinic who underwent 3 Tesla hip MRI scans with intra-articular contrast agent. A validated artificial intelligence based algorithm was utilized for automated segmentation and the calculation of 3D outcome parameters.
Study NCT05086627 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: Patients were treated with short-course neoadjuvant radiotherapy
Study NCT05086627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine+Oxaliplatin
Description: Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
Study NCT05086627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine+Oxaliplatin
Description: Patients were treated with neoadjuvant chemotherapy with CapeOX (Capecitabine+Oxaliplatin).
Study NCT05431062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0.25
Study NCT05444452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanatation of Genoss DES sirolimus-eluting coronary system
Description: Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
Study NCT05444452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanatation of Xience DES everolimus-eluting coronary system
Description: Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
Study NCT04733963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib Plus Capecitabine
Description: Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study NCT04733963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Plus Capecitabine
Description: Maintenance therapy with bevacizumab at the dose 5mg/kg q2w (Q2W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study NCT06207383 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conduction system pacing
Description: Conduction system pacing (either His bundle pacing or left bundle branch area pacing)
Study NCT06207383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrioventricular nodal ablation
Description: Catheter ablation of the atrioventricular node